Comparative Pharmacology
Head-to-head clinical analysis: BEYAZ versus JENLOGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEYAZ versus JENLOGA.
BEYAZ vs JENLOGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone suppresses gonadotropins (FSH and LH) from the pituitary, inhibiting ovulation, altering cervical mucus, and inducing endometrial changes. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
One tablet (drospirenone 3 mg / ethinyl estradiol 0.02 mg) orally once daily for 24 days, followed by 4 days of placebo.
350 mg orally once daily with food.
None Documented
None Documented
Drospirenone: approximately 30 hours (terminal). Ethinyl estradiol: approximately 13-15 hours (terminal). Steady-state reached within 10 days. Clinical context: once-daily dosing maintains therapeutic levels with minimal accumulation after 3-4 cycles.
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Urine (45-55% as metabolites), feces (30-40% as metabolites), with enterohepatic recirculation of ethinyl estradiol metabolites.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Category C
Category C
Oral Contraceptive
Oral Contraceptive